Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Status:
Completed
Trial end date:
1999-11-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Assess the efficacy of poloxamer 188 in reducing the duration of painful
vaso-occlusive crisis in patients with sickle cell disease.
II. Assess the effect of poloxamer 188 on duration and intensity of pain, total analgesic
use, and length of hospitalization of these patients.